Department of Interventional Therapy, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, no. 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Department of Medical Ultrasound, Division of Interventional Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, no. 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Biomark Med. 2021 Oct;15(14):1277-1288. doi: 10.2217/bmm-2020-0795. Epub 2021 Sep 6.
The potential of long noncoding RNA in hepatocellular carcinoma (HCC) has led to promising insights into therapeutic intervention. The clinical significance of in HCC is unclear. This study aimed to evaluate the predictive value of a novel long noncoding RNA, , for the prognosis of patients with HCC. Between December 2005 and November 2011, 125 and 75 HCC patients in the training and validation groups, respectively, who underwent liver surgery were included in our study. The expression of HCC and corresponding nontumor liver tissues was detected using microarray and reverse transcription quantitative polymerase chain reaction (RT-qPCR). These HCC patients were assigned into high and low expression groups based on the threshold of the receiver operating characteristic curve. Kaplan-Meier analysis was performed to determine the prognosis of HCC patients. expression was upregulated in paired tumor samples compared with corresponding nontumor samples in the two groups. The area under the receiver operating characteristic curve for the levels of in the diagnosis of HCC was 0.66, 95% CI: 0.59-0.73. HCC patients with high expression had significantly worse tumor recurrence-free, metastasis-free, disease-free and overall survival than those with low expression. is negatively correlated with the prognosis of HCC and provides a promising strategy for the treatment and prognosis of HCC.
长链非编码 RNA 在肝细胞癌（HCC）中的潜力，为治疗干预提供了有前景的见解。 在 HCC 中 的临床意义尚不清楚。本研究旨在评估一种新型长链非编码 RNA， 在预测 HCC 患者预后方面的价值。
在 2005 年 12 月至 2011 年 11 月期间，我们分别在训练组和验证组纳入了 125 例和 75 例接受肝切除术的 HCC 患者。使用微阵列和逆转录定量聚合酶链反应 (RT-qPCR) 检测 HCC 和相应非肿瘤肝组织中的 表达。根据受试者工作特征曲线的阈值，将这些 HCC 患者分为高和低 表达组。通过 Kaplan-Meier 分析确定 HCC 患者的预后。与两组中的相应非肿瘤样本相比，配对的肿瘤样本中 表达上调。 水平用于 HCC 诊断的受试者工作特征曲线下面积为 0.66，95%CI：0.59-0.73。高 表达的 HCC 患者在肿瘤无复发生存、无转移生存、无疾病生存和总生存方面明显差于低 表达的患者。 在 HCC 患者中， 表达与预后呈负相关，为 HCC 的治疗和预后提供了有前景的策略。
